Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Mesothelioma, Malignant 1

Interventions

pembrolizumab 120Carboplatin 114Pemetrexed 74Cisplatin 71Nivolumab 68Paclitaxel 58Docetaxel 56Radiotherapy 41Erlotinib Hydrochloride 41Gemcitabine 35Etoposide 34atezolizumab 30osimertinib 29Cetuximab 27Ipilimumab 25Bevacizumab 25Radiosurgery 22durvalumab 21Cyclophosphamide 20Drug Therapy 18130-nm albumin-bound paclitaxel 17avelumab 14Taxes 14Gefitinib 14Albumin-Bound Paclitaxel 14Irinotecan 13Injections 13fludarabine 11Radiation 11cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × methoxyamine × Thoracic × Clear all
NCT02535312 2026-04-17

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
30 enrolled 15 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡